Effects of Antihypertensive Treatment on Systolic Blood Pressure and Renin in Experimental Hypertension in Rats

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 1979 Feb 1

PMID 762665

Citations 6

Authors

J L Cangiano

M MARTINEZ-MALDONADO

Affiliations

Soon will be listed here.

Abstract

The effects of pretreatment with hydralazine and alpha-methyldopa were assessed in rats made hypertensive by ligation of the left renal artery (LRA). Systolic blood pressure and peripheral renin activity (PRA) were measured 7 and 1 day before LRA and 2, 7 and 28 days after LRA. Systolic blood pressure increased 2 days after LRA in control and alpha-methyldopa-treated rats but not in the hydralazine-treated rats. Peripheral renin activity levels did not correlate with changes in systolic blood pressure. Peripheral renin activity first increased 7 days after LRA but decreased 28 days after LRA despite persistent hypertension in controls and alpha-methyldopa-treated rats. It is concluded that factors other than renin are involved in the initial and maintenance phases of this experimental model. In addition, hydralazine protects the rat with LRA from developing hypertension.

Citing Articles

Strength Training Reduces Cardiac and Renal Oxidative Stress in Rats with Renovascular Hypertension.

Miguel-Dos-Santos R, Santos J, Macedo F, Marcal A, Santana Filho V, Wichi R Arq Bras Cardiol. 2021; 116(1):4-11.

PMID: 33566958 PMC: 8159508. DOI: 10.36660/abc.20190391.

Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.

Hilditch A, Prior H, Drew G Br J Pharmacol. 1996; 118(3):711-9.

PMID: 8762098 PMC: 1909712. DOI: 10.1111/j.1476-5381.1996.tb15458.x.

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Wienen W, Hauel N, van Meel J, Narr B, Ries U, Entzeroth M Br J Pharmacol. 1993; 110(1):245-52.

PMID: 8220885 PMC: 2175984. DOI: 10.1111/j.1476-5381.1993.tb13800.x.

Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

Hilditch A, Hunt A, Gardner C, Twissell D, Polley J, Travers A Br J Pharmacol. 1994; 111(1):137-44.

PMID: 8012689 PMC: 1910000. DOI: 10.1111/j.1476-5381.1994.tb14035.x.

Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.

Cirillo R, Renzetti A, Cucchi P, Guelfi M, Salimbeni A, Caliari S Br J Pharmacol. 1995; 114(6):1117-24.

PMID: 7620700 PMC: 1510339. DOI: 10.1111/j.1476-5381.1995.tb13323.x.